아미노글리코사이드 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of aminoglycosides Market

The global aminoglycosides market was valued at USD 1.92 billion in 2025 and is projected to reach USD 1.96 billion in 2026, eventually growing to USD 2.52 billion by 2034, reflecting a CAGR of 3.17% during the forecast period. North America dominated the market in 2025 with a 41.31% share, owing to robust healthcare infrastructure, high purchasing capacity, and a strong presence of key players. Aminoglycosides are a class of bactericidal antibiotics widely employed in treating complicated urinary tract infections (cUTIs), sepsis, nosocomial pneumonia, and respiratory diseases like cystic fibrosis. Drugs such as neomycin, tobramycin, gentamicin, amikacin, paromomycin, and streptomycin remain vital in clinical practice, particularly in critical care settings due to their synergy with B-lactam antibiotics against multidrug-resistant organisms. Technological advances, including inhaled forms and semi-synthetic derivatives, have improved drug delivery and safety profiles. Leading companies like Hikma Pharmaceuticals PLC, Pfizer Inc., and Cipla maintain market dominance through extensive product portfolios and geographic expansion.

Market Dynamics

Drivers: Rising incidences of urinary tract infections (UTIs) have increased aminoglycoside prescriptions. Factors such as an aging population, higher prevalence of diabetes, and hospital-acquired infections in developing regions have contributed to this growth. For instance, in February 2024, Cipla Limited received approval from India's CDSCO for Plazomicin, a new IV aminoglycoside indicated for complicated UTIs, including pyelonephritis.

Restraints: The emergence of antimicrobial resistance (AMR) threatens market growth. Resistance in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa has been rising, complicating treatment outcomes. In July 2023, the U.S. CDC reported an increase in carbapenem-resistant Enterobacteriaceae (CRE) and aminoglycoside-resistant gram-negative bacteria. Similarly, the ECDC noted resistance in K. pneumoniae bloodstream infections exceeding 25% in multiple EU countries.

Opportunities: Development of peptide-linked aminoglycoside conjugates offers potential to combat multidrug-resistant pathogens. In August 2025, a study published in Frontiers in Microbiology highlighted that peptide-neomycin conjugates combined with polymyxin B show synergistic activity against multidrug-resistant gram-negative bacteria, presenting a promising growth avenue.

Challenges: Ototoxicity and nephrotoxicity remain major concerns. Patients with rare mitochondrial mutations are particularly susceptible to irreversible hearing loss, even at therapeutic doses. In January 2021, the UK government reported the narrow therapeutic window of aminoglycosides, highlighting the clinical challenges in urgent care settings and limiting adoption.

Market Trends

The market is witnessing increased adoption of combination therapy. Aminoglycosides are now frequently integrated into multidrug regimens for conditions like NTM lung disease caused by Mycobacterium avium complex (MAC). This approach enhances efficacy, slows resistance development, and extends the therapeutic lifespan of existing antibiotics. In March 2021, Insmed Inc. received approval in Japan for ARIKAYCE (amikacin liposome inhalation suspension), a combination therapy for NTM lung disease.

Segmentation Analysis

By Generation: The third-generation aminoglycosides dominate due to effectiveness against multidrug-resistant infections. Strategic collaborations, such as the June 2022 agreement between Sihuan Pharmaceutical Holdings Group Ltd. and Shanghai SPH New Asia Pharmaceutical Co., Ltd., support the development of third-generation drugs like Plazomicin.

By Application: Respiratory tract infections hold the largest share due to their prevalence and treatment complexity, particularly in cystic fibrosis patients. The CDC reported in May 2024 that approximately 35,000 people in the U.S. are affected by cystic fibrosis, driving aminoglycoside demand.

By Route of Administration: The topical segment dominates due to localized efficacy, minimal systemic absorption, and novel product launches. For example, Appili Therapeutics Inc. developed ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis, in October 2024.

By Distribution Channel: Retail pharmacies lead due to accessibility, patient trust, and network expansion. In September 2024, Pharmaprix expanded its care clinics in Quebec, improving access to aminoglycosides.

Regional Outlook

North America: Dominates with USD 0.79 billion in 2025, driven by strategic collaborations, R&D investments, and a robust healthcare system.

Europe: Projected to reach USD 0.49 billion in 2025 with a 2.80% growth rate, supported by strong healthcare infrastructure and antimicrobial stewardship programs.

Asia Pacific: Estimated at USD 0.32 billion in 2025, reflecting increasing access to antibiotics and rising infection prevalence.

Latin America & Middle East & Africa: Moderate growth is expected, with USD 0.20 billion in Latin America and smaller contributions from the Middle East & Africa, fueled by increasing healthcare expenditure.

Competitive Landscape

The market exhibits a semi-concentrated structure. Key players like Amneal Pharmaceuticals, Hikma Pharmaceuticals, Cipla, Pfizer Inc., and Insmed Incorporated focus on product innovation, partnerships, and geographic expansion. Notable developments include Nordic Pharma's generic Maxitrol launch in April 2025 and Lupin's Tobramycin inhalation solution FDA approval in June 2018.

Conclusion

The global aminoglycosides market is set to grow from USD 1.92 billion in 2025 to USD 1.96 billion in 2026, reaching USD 2.52 billion by 2034 at a CAGR of 3.17%. Growth is driven by rising urinary tract and respiratory infections, combination therapy adoption, and ongoing R&D to overcome antimicrobial resistance. Challenges such as toxicity risks and resistance issues exist, but advancements in formulation, delivery technologies, and peptide-linked aminoglycosides present significant opportunities. Key players' strategic collaborations and product launches reinforce their market position, ensuring sustained growth over the forecast period.

Segmentation By Generation

• First Generation
• Second Generation
• Third Generation
• Others

By Application

• Urinary Tract Infections
• Respiratory Tract Infection
• Skin Infections
• Ophthalmic Infections
• Others

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
• 4.2. Regulatory Scenario by Key Countries/ Region, 2025
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview of Antimicrobial Treatment Guidelines
• 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
• 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Generation
  • 5.1.1. First Generation
  • 5.1.2. Second Generation
  • 5.1.3. Third Generation
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Urinary Tract Infections
  • 5.2.2. Respiratory Tract Infection
  • 5.2.3. Skin Infections
  • 5.2.4. Opthalmic Infections
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Topical
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Generation
  • 6.1.1. First Generation
  • 6.1.2. Second Generation
  • 6.1.3. Third Generation
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Urinary Tract Infections
  • 6.2.2. Respiratory Tract Infection
  • 6.2.3. Skin Infections
  • 6.2.4. Opthalmic Infections
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Topical
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Generation
  • 7.1.1. First Generation
  • 7.1.2. Second Generation
  • 7.1.3. Third Generation
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Urinary Tract Infections
  • 7.2.2. Respiratory Tract Infection
  • 7.2.3. Skin Infections
  • 7.2.4. Opthalmic Infections
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Topical
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Generation
  • 8.1.1. First Generation
  • 8.1.2. Second Generation
  • 8.1.3. Third Generation
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Urinary Tract Infections
  • 8.2.2. Respiratory Tract Infection
  • 8.2.3. Skin Infections
  • 8.2.4. Opthalmic Infections
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Topical
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Generation
  • 9.1.1. First Generation
  • 9.1.2. Second Generation
  • 9.1.3. Third Generation
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Urinary Tract Infections
  • 9.2.2. Respiratory Tract Infection
  • 9.2.3. Skin Infections
  • 9.2.4. Opthalmic Infections
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Generation
  • 10.1.1. First Generation
  • 10.1.2. Second Generation
  • 10.1.3. Third Generation
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Urinary Tract Infections
  • 10.2.2. Respiratory Tract Infection
  • 10.2.3. Skin Infections
  • 10.2.4. Opthalmic Infections
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Topical
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Amneal Pharmaceuticals, Inc.
  • 11.2.2. Hikma Pharmaceuticals PLC
  • 11.2.3. Insmed Incorporated
  • 11.2.4. Pfizer Inc.
  • 11.2.5. Cipla
  • 11.2.6. Nordic Group B.V.
  • 11.2.7. Lupin
  • 11.2.8. Sun Pharmaceutical Industries Ltd.
  • 11.2.9. Dr. Reddy's Laboratories Ltd.